There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Novavax stock was climbing again on Monday after the company expressed new confidence in the eventual approval of its ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax WASHINGTON -- The Trump administration's effort to impose new ...

Full approval from the FDA means a product can stay on the market even after a health emergency ends. HealthDay News — Novavax’s COVID-19 vaccine could soon receive full approval from the US ...

You can reach Helen on Signal at hbranswell.01. Confusion over the Food and Drug Administration’s delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend when ...